This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.
Urine sample in existing biorepository
High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines
Scheduled to undergo nephrectomy
Does not meet inclusion criteria
Mayo Clinic patients scheduled to undergo nephrectomy for treatment of RCC.
Case-control
Prospective
Proteomic profiling of urinary EVs
Other interventionEV isolation and mass spectrometry.
Blood sample collection
Procedure/SurgeryBlood samples collected pre- and post-nephrectomy
Differentiate tumor-derived extracellular vesicle (tdEV) surface proteins expressed in benign vs malignant renal tumors
Differential protein expression analysis will be performed on stored urine samples from a biorepository to identify tdEV proteins in each renal cell carcinoma (RCC) subtype (clear-cell, papillary, and chromophobe) versus benign.
Prediction of metastasis after surgery
Blood samples will be collected pre-and post-nephrectomy to asses for tdEV levels which will be correlated with clinicopathological features to test whether tdEV levels can be used to better predict likelihood of metastasis in patients undergoing curative-intent radical nephrectomy.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
